BJMO - volume 18, issue 7, november 2024
C. Artigas MD, PhD, A.M. Bergman MD, PhD, M. Gizzi MD, I.J. de Jong MD, PhD, D.E. Oprea-Lager MD, PhD, W.J.G. Oyen MD, PhD, M. Strijbos MD, PhD
The life expectancy and quality of life of patients with metastatic castration-resistant prostate cancer (mCRPC) continue to improve with the registration of new therapies. However, for individual patients, the appropriateness and optimal sequence of taxanes, radium-223, androgen receptor pathway inhibitors and lutetium-177-prostate-specific membrane antigen (PSMA) remains to be determined. To assess the current positioning of radium-223 and lutetium-177-PSMA as treatments for mCRPC, a consensus meeting with a multidisciplinary panel of experts from the Netherlands and Belgium was held. This article summarises the panel’s guidance on preferred sequences and the discussions of that meeting.
(BELG J MED ONCOL 2024;18(7):258–267)
Read moreBJMO - 2019, issue Special, march 2019
C. Artigas MD, PhD, prof. dr. Piet Dirix
PSMA is a type II transmembrane glycoprotein that is highly expressed in almost all prostate cancer (PCa) cells, with only 5–10% of primary PCa not having PSMA expression. The recent development of radiotracers directed against PSMA has taken things to a new level. There is now a solid body of evidence for the performance of 68Ga-PSMA PET/CT in secondary staging (i.e. at PSA rise after primary treatment), with an ability to accurately detect small volume disease at far lower serum PSA levels than with bone scan or even choline PET/CT. As a result, the use of 68Ga-PSMA PET/CT as a diagnostic adjunct is becoming increasingly mainstream. In addition to this, radioligand therapy is emerging as a new therapeutic strategy in PCa. In the final presentation of the 2019 annual BMUC meeting, dr. Carlos Artigas discussed the potential of PSMA-PET in staging and assessing biochemical recurrence in prostate cancer (PCa) patients after which dr. Piet Dirix listed up some critical notes with respect to the use of PSMA in the evaluation of biochemical recurrence.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
